Stereotaxis, Inc. (STXS)
NYSEAMERICAN: STXS · Real-Time Price · USD
1.760
-0.040 (-2.22%)
Mar 31, 2025, 4:00 PM EST - Market closed
Stereotaxis Revenue
In the year 2024, Stereotaxis had annual revenue of $26.92M with 0.55% growth. Stereotaxis had revenue of $6.34M in the quarter ending December 31, 2024, with 38.88% growth.
Revenue (ttm)
$26.92M
Revenue Growth
+0.55%
P/S Ratio
5.57
Revenue / Employee
$193,655
Employees
139
Market Cap
151.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.92M | 147.00K | 0.55% |
| Dec 31, 2023 | 26.77M | -1.38M | -4.89% |
| Dec 31, 2022 | 28.15M | -6.87M | -19.63% |
| Dec 31, 2021 | 35.02M | 8.39M | 31.51% |
| Dec 31, 2020 | 26.63M | -2.27M | -7.86% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
STXS News
- 12 days ago - Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program - GlobeNewsWire
- 21 days ago - Stereotaxis to Present at 37th Annual Roth Conference - GlobeNewsWire
- 24 days ago - Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn - Seeking Alpha
- 4 weeks ago - Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery - GlobeNewsWire
- 4 weeks ago - Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance - GlobeNewsWire
- 4 weeks ago - Stereotaxis Reports 2024 Full Year Financial Results - GlobeNewsWire
- 4 weeks ago - Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference - GlobeNewsWire